ProPhase Labs

ProPhase Labs Inc. is a publicly traded (Nasdaq: PRPH) company focused on biotechnology, genomics, and diagnostics. Headquartered in Doylestown, Pennsylvania, ProPhase employs 73 people and generates an annual revenue of $50 million. ProPhase Labs develops and commercializes a range of health and wellness solutions, including industry-leading Whole Genome Sequencing technology. Their efforts in cancer research center around a potentially life-saving test for early detection of esophageal cancer and innovative cancer therapeutics with novel mechanisms of action. In addition, the company operates CLIA certified labs equipped with cutting-edge diagnostic technology, offering wellness solutions to both healthcare providers and individual consumers. ProPhase Labs distinguishes itself through its commitment to executional excellence, strategic diversification, and a comprehensive, omni-channel approach to healthcare solutions. They strive to provide consumers with the tools and resources necessary to achieve optimal health and well-being. Those interested in learning more about ProPhase Labs and its offerings can visit their website at prophaselabs.com.